Stemline Therapeutics Inc. (NASDAQ:STML)’s share price rose 6.9% on Tuesday . The company traded as high as $8.85 and last traded at $7.91, with a volume of 1,109,139 shares trading hands. The stock had previously closed at $7.40.

Several equities research analysts recently issued reports on the company. Jefferies Group reissued a “buy” rating and issued a $23.00 price objective on shares of Stemline Therapeutics in a research note on Monday, June 6th. Roth Capital reissued a “buy” rating and issued a $32.00 price objective on shares of Stemline Therapeutics in a research note on Tuesday, May 10th. Zacks Investment Research raised Stemline Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 price objective for the company in a research note on Wednesday, July 6th. Finally, Wedbush reissued an “outperform” rating and issued a $15.00 price objective on shares of Stemline Therapeutics in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Stemline Therapeutics has a consensus rating of “Buy” and an average price target of $19.31.

The stock’s market capitalization is $142.60 million. The firm has a 50 day moving average price of $7.31 and a 200-day moving average price of $6.15.

Stemline Therapeutics (NASDAQ:STML) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. On average, analysts anticipate that Stemline Therapeutics Inc. will post ($2.11) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Stemline Therapeutics stock. Royce & Associates LLC boosted its position in Stemline Therapeutics Inc. (NASDAQ:STML) by 318.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 159,179 shares of the biopharmaceutical company’s stock after buying an additional 121,179 shares during the period. Royce & Associates LLC owned about 0.91% of Stemline Therapeutics worth $1,004,000 as of its most recent SEC filing.

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.